Flecainide is a class Ic antiarrhythmic agent used to manage atrial fibrillation and paroxysmal supraventricular tachycardias (PSVT). Flecainide is a Class I anti-arrhythmic agent like encainide and propafenone.
- Mechanism
- Curator reviewed · 4 references
Flecainide blocks fast inward sodium channels and slowly unbinds during diastole, prolonging the refractory period of the heart. This blockade also shortens the duration of action potentials through the Purkinjie fibers. Flecainide also prevents delayed rectifier potassium channels from opening, lengthening the action potential through ventricular and atrial muscle fibers. Finally, flecainide also blocks ryanodine receptor opening, reducing calcium release from sarcoplasmic reticulum, which reduces depolarization of cells.
- Primary indication
- In New Zealand and America, flecainide is indicated to prevent supraventricular arrhythmias and ventricular arrhythmias.Curator reviewed · 8 structured indications
- Formula / weight
- C17H20F6N2O3 · 414.3427 g/mol (avg)
- First approval
- Canada, 2016 · United States, 1985
- Also known as
- Flecaine
- Code names
- CCRIS 313
- Brand names
Resolves to
DJBNUMBKLMJRSA-UHFFFAOYSA-NSMILESFC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Flecainide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account